1. Study shows effectiveness of micropulse TSCPC for glaucoma
A five-year study investigating the use of micropulse transscleral cyclophotocoagulation (TSCPC) and how it affects intraocular pressure (IOP) in patients with glaucoma has been published in Ophthalmology and Therapy.
The authors judged micropulse TSCPC to be safe and effective as a treatment for reducing IOP and the number of IOP-lowering medications required. It was also deemed a viable alternative for patients after failed incisional glaucoma surgery.
Researchers conducted a retrospective analysis of 165 patients with glaucoma in the Netherlands between 2016 and 2019.
The study saw an IOP reduction or a stable postoperative IOP with fewer medications in 70.8% of patients after five years.
Sign in to continue
Not already a member of the College?
Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
Glaucoma is the second leading cause of irreversible sight loss in the UK and affects over one million people, which is predicted to rise by 100,000 cases to 1.145 million people by 2030*.
The College of Optometrists has published its first issue of Ophthalmic and Physiological Optics (OPO), its flagship international and interdisciplinary research journal for contemporary vision science and optometry, with its new publishing partner Springer Nature this month.